Notice of Results

RNS Number : 6003P

Allergy Therapeutics PLC

27 March 2009

 



Friday 27 March 2009

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Results Notification

Allergy Therapeutics (AGY), the specialist pharmaceutical company focused on allergy vaccination, will be announcing its interim results for the six months ended 31 December 2008, on Tuesday 31 March 2009.  

An analyst meeting will be held at the offices of Financial Dynamics, 26 Southampton Buildings, London, WC2A 1PB at 9.30am, with registration and coffee from 9.15am.  

For further information

Allergy Therapeutics	[phone]
Keith Carter, Chief Executive
Ian Postlethwaite, Finance Director
Nomura Code Securities	[phone]
Juliet Thompson
Financial Dynamics	[phone]
Ben Brewerton
Susan Quigley

About Allergy Therapeutics

Allergy Therapeutics plc is a London Stock Exchange (AIM) listed, integrated specialist pharmaceutical company focused on allergy vaccination. It has a growing, profitable core business achieving sales of allergy vaccines of £31 million for the year ended June 2008 in Germany, Italy, Spain and other EU markets through its own sales and marketing infrastructure. The Company is expanding its infrastructure with operations also in the United Kingdom, Poland, the Czech Republic, Slovakia and Austria.

 

END

 

 

NORMGGZFGNZGLZM